Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Friday 14 February, 2020

Morgan Stanley&CoLLC

Rule 38.5 - Replacemement ALLERGAN PLC

RNS Number : 1061D
Morgan Stanley & Co. LLC
14 February 2020
 

AMENDMENT               Section 2(c)(ii) 

 

 FORM 38.5

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER  RULES, 2007 (AS AMENDED)

 

DEALINGS BY CONNECTED EXEMPT MARKET-MAKERS

 

1.             KEY INFORMATION

 Name of exempt market-maker

   Morgan Stanley & Co. LLC

 Company dealt in

   ALLERGAN PLC

 Class of relevant security to which the dealings being disclosed relate (Note 1)

  US$0.0001 ORDINARY SHARES

 Date of dealing

   12 FEBRUARY 2020

 

 

2.             DEALINGS (Note 2)

 

(a)           Purchases and sales

 Total number of relevant secuities accquired

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

  314,488

 202.2150 USD

 200.6900 USD

 

 Total number of relevant secuities disposed

 Highest price paid (Note 3)

 Lowest price paid (Note 3)

  313,916

 202.2150 USD

 200.7500 USD

 

 

(b)           Derivatives transactions (other than options transactions)

 

 Product name, e.g. CFD

 Nature of transaction

                (Note 4)

 Number of relevant securities

                (Note 5)

 Price per unit

 N/A

 N/A

 N/A

 N/A

 

 

(c)            Options transactions in respect of existing relevant securities

 

i)           Writing, selling, purchasing or varying

 

 Product name, eg call option

 Writing, selling, purchasing, varying etc

 Number of securities to which the option relates (Note 5)

 Exercise Price

 Type, e.g American, European etc

 Expiry Date

 Option money paid/received per unit (Note 3)

 CALL

 PURCHASE

 100

 202.5000

A

 21/02/2020

 0.8000 USD

 CALL

 PURCHASE

 300

 200.0000

A

 14/02/2020

 1.6800 USD

 CALL

 PURCHASE

 300

 200.0000

A

 14/02/2020

 2.1400 USD

 CALL

 PURCHASE

 100

 197.5000

A

 21/02/2020

 3.7200 USD

 CALL

 PURCHASE

 100

 195.0000

A

 21/02/2020

 6.4100 USD

 PUT

 SALE

 200

 160.0000

A

 21/02/2020

 0.0900 USD

 CALL

 SALE

 100

 200.0000

A

 14/02/2020

 1.5400 USD

 

(ii) Exercising

 

 Product name, eg call option

 Number of securities

 Exercise price per unit (Note 3)

CALL

100

155.0000 USD

CALL

2,400

150.0000 USD

CALL

900

145.0000 USD

CALL

800

125.0000 USD

CALL

100

170.0000 USD

CALL

200

197.5000 USD

CALL

100

192.5000 USD

CALL

100

190.0000 USD

CALL

7,200

140.0000 USD

CALL

1,900

140.0000 USD

CALL

900

130.0000 USD

CALL

500

120.0000 USD

CALL

100

110.0000 USD

CALL

900

100.0000 USD

CALL

2,400

140.0000 USD

CALL

400

160.0000 USD

CALL

5,100

150.0000 USD

CALL

900

160.0000 USD

CALL

600

195.0000 USD

CALL

100

192.5000 USD

CALL

300

190.0000 USD

CALL

200

190.0000 USD

CALL

200

190.0000 USD

CALL

1,300

180.0000 USD

CALL

2,300

200.0000 USD

CALL

100

195.0000 USD

 

 

3. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full Details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 Date of disclosure

 14 FEBRUARY 2020

 Contact Name

Craig Horsley

 Telephone Number

+44(141) 245 7736

 Name of offeree/offeror with which connected

ABBVIE INC.

Nature of connection (Note 6)

Advisory

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEGPURUPUPUGAC

a d v e r t i s e m e n t